Cognitive Processing Therapy for Post Traumatic Stress Disorder (PTSD)

Phase-Based Progress Estimates
Post Traumatic Stress Disorder (PTSD)
Cognitive Processing Therapy - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial is designed to compare the effectiveness of 1-week virtual massed Cognitive Processing Therapy (CPT) to 5-day virtual relaxation training (RT) with regard to their ability to reduce posttraumatic stress disorder (PTSD) symptoms.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Post Traumatic Stress Disorder (PTSD)

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Through study completion, an average of 8 months

Month 8
Clinician-Administered PTSD Scale for DSM
PTSD Checklist for DSM-5 Criteria

Trial Safety

Safety Progress

1 of 3

Other trials for Post Traumatic Stress Disorder (PTSD)

Trial Design

2 Treatment Groups

Relaxation Training (RT)
1 of 2
Cognitive Processing Therapy (CPT)
1 of 2
Active Control
Experimental Treatment

140 Total Participants · 2 Treatment Groups

Primary Treatment: Cognitive Processing Therapy · No Placebo Group · N/A

Cognitive Processing Therapy (CPT)
Experimental Group · 1 Intervention: Cognitive Processing Therapy · Intervention Types: Behavioral
Relaxation Training (RT)
ActiveComparator Group · 1 Intervention: Relaxation Training · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Processing Therapy

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 8 months

Who is running the clinical trial?

Rush University Medical CenterLead Sponsor
379 Previous Clinical Trials
150,957 Total Patients Enrolled
8 Trials studying Post Traumatic Stress Disorder (PTSD)
517 Patients Enrolled for Post Traumatic Stress Disorder (PTSD)

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.